Stereotaxis Ord Stock Price, News & Analysis

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, announced it will release its 2024 third quarter financial results on November 11, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments. Stereotaxis technology has been used to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions.

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced its participation in the Society for Cardiac Robotic Navigation's Annual Meeting on October 28-29 in Lisbon, Portugal. The conference will feature over forty physicians from across the globe, showcasing Stereotaxis' robotic technologies in presentations, panels, and demonstrations.

Key topics include:

• Artificial intelligence and robotic automation in cardiology
• Clinical experience with the MAGiC ablation catheter and Abbott's EnSite X mapping system
• Robotic catheter innovations for high-density mapping and pulsed field ablation
• Advancements in Genesis and GenesisX robotic systems
• Alternative access techniques from the arm
• Best practices for robotics in complex arrhythmia treatment

David Fischel, Stereotaxis Chairman and CEO, expressed excitement about the conference, noting the growing importance of robotics in advancing cardiology.

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has announced its participation in two upcoming investor conferences. David Fischel, Chairman and CEO, will represent the company at both events:

1. H.C. Wainwright 26th Annual Global Investment Conference on September 11th, 2024, where he will present a company overview at 12:30 pm EST and be available for one-on-one meetings.

2. Lake Street 8th Annual Best Ideas Growth Conference on September 12, 2024, where he will be available for one-on-one meetings.

Fischel expressed appreciation for the opportunity to share Stereotaxis' ongoing technological, commercial, and strategic progress with investors. Interested parties can arrange meetings through conference registration.

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced its technology will be featured at the upcoming HRX digital health conference from September 5-7, 2024, in Atlanta. The conference, initiated by the Heart Rhythm Society, focuses on digital technologies advancing cardiovascular medicine.

CEO David Fischel will participate in two key sessions:

• A roundtable discussion on "The EP Lab of the Future" on September 5th at 4:45 PM EDT
• A joint session on "The Role of Robotics in Present and Future Care of Heart Rhythm Patients" on September 6th at 9:45 AM EDT

These sessions underscore the growing importance of robotic technology in improving patient outcomes and advancing cardiac rhythm management.

Stereotaxis (NYSE: STXS) reported its 2024 Q2 financial results, highlighting strategic progress despite commercial challenges. Key achievements include CE mark approval for GenesisX in Europe, 510(k) submission in the US, and progress on MAGiC regulatory reviews. The company also completed the acquisition of Access Point Technologies.

Q2 revenue was $4.5 million, down from $7.9 million in Q2 2023. System revenue was $0.2 million, while recurring revenue was $4.3 million. The gross margin was 74%. Operating expenses were $9.3 million, including $2.5 million in non-cash stock compensation. The company reported an operating loss of $6.0 million and a net loss of $5.8 million. Stereotaxis ended the quarter with $15.2 million in cash and no debt.

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has achieved significant milestones for its next-generation robotic system, GenesisX. The company has obtained CE mark in Europe and submitted a 510(k) application to the FDA in the US. GenesisX builds upon the established benefits of Robotic Magnetic Navigation (RMN) systems while reducing adoption barriers for hospitals.

Key improvements include smaller magnets, integrated magnetic shielding, no need for structural anchoring, standard power requirements, and an 80% smaller system cabinet. These advancements significantly reduce installation complexities and costs. Stereotaxis plans to launch GenesisX in 2025, focusing on regulatory approvals for compatible catheters, real-world demonstrations, and preparing supply chain and commercial processes.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced it will release its 2024 second quarter financial results on Monday, August 12, 2024 after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. EST to discuss the results and corporate developments.

Interested parties can access the live call by dialing 800-715-9871 (US and Canada) or 1-646-307-1963 (International) with the participant pass code 7734844. A live and replay webcast will be available on the investor relations section of Stereotaxis' website. A phone replay will be accessible for one month following the call.

Stereotaxis, listed on the NYSE, is a global leader in innovative surgical robotics, focusing on minimally invasive endovascular interventions. Their technology has been used to treat over 100,000 patients worldwide.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has appointed Nachum "Homi" Shamir to its Board of Directors. Shamir brings significant experience in growing global commercial organizations, scaling high-technology medical device operations, and executing successful mergers and acquisitions. He previously served as CEO of Luminex and Given Imaging, both of which were sold for over $1 billion each. Shamir currently chairs Mediwound and SSI Diagnostica.

This strategic appointment comes as Stereotaxis approaches significant inflection points. The company aims to benefit from Shamir's expertise in growing global commercial and operational capabilities, and refining its strategy to transform endovascular surgery through robotics. Stereotaxis' technology has been used to treat over 100,000 patients globally.

Penn Presbyterian Medical Center (PPMC) announces the successful implementation of the Genesis Robotic Magnetic Navigation System for treating heart rhythm patients, becoming the first hospital in the Northeast U.S. to adopt this advanced technology.

Developed by Stereotaxis (NYSE: STXS), the Genesis System enhances the precision and safety of cardiac ablation procedures used to treat arrhythmias—abnormal heart rhythms that affect millions globally and can lead to severe conditions like stroke and heart failure if untreated.

Dr. Benjamin D’Souza, Cardiac Electrophysiologist at PPMC, emphasized the system's role in improving patient outcomes by allowing tailored treatments. Stereotaxis CEO David Fischel expressed enthusiasm about the partnership, anticipating significant advancements in patient care and clinical research.